MedDRA preferred term · swelling of the voice box

Laryngeal oedema: adverse event reports recording this term

6,050 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

6,050
reports recording the term: 0% of all reports; 330
reports, 12 months to June 2026: 289 in the 12 months before; 98.4%
marked serious by the reporter: 57.4% across all reports; 5.2%
record death among outcomes, as reported: 9.1% across all reports

"Laryngeal oedema" (in plain words, swelling of the voice box) is a MedDRA preferred term recorded in 6,050 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

330 reports recorded it in the 12 months to June 2026, up 14% from 289 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 98.4% are marked serious, 5.2% include death among the outcomes and 36.4% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Oxaliplatin, Ibuprofen and Ultravist. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Oxaliplatin	Platinum-based drug	158	0.2%
Ibuprofen	Nonsteroidal anti-inflammatory drug	123	0.2%
Ultravist	Radiographic contrast agent	115	1.6%
Remicade	Tumor necrosis factor blocker	105	0.1%
Firazyr	Bradykinin B2 receptor antagonist	98	3.2%
Xolair	Anti-IgE	91	0.1%
Humira	—	88	0%
Lisinopril	Angiotensin converting enzyme inhibitor	86	0.2%
Amoxicillin	Penicillin-class antibacterial	82	0.3%
Mabthera	—	78	0.4%
Cinryze	Human C1 esterase inhibitor	77	2.9%
Ramipril	Angiotensin converting enzyme inhibitor	68	0.2%
Carboplatin	Platinum-based drug	62	0.1%
Acetaminophen	Nonsteroidal anti-inflammatory drug	54	0.1%
Fluorouracil	Nucleoside metabolic inhibitor	54	0.1%
Aspirin	Nonsteroidal anti-inflammatory drug	53	0.1%
Docetaxel	Microtubule inhibitor	53	0.1%
Omnipaque	Radiographic contrast agent	53	0.7%
Paclitaxel	Microtubule inhibitor	53	0.1%
Rituximab	CD20-directed cytolytic antibody	51	0%
Cisplatin	Platinum-based drug	44	0.1%
Levofloxacin	Fluoroquinolone antibacterial	42	0.1%
Enbrel	Tumor necrosis factor blocker	35	0%
Dotarem	Gadolinium-based contrast agent	33	1.1%
Erbitux	Epidermal growth factor receptor antagonist	33	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Nonsteroidal anti-inflammatory drug	326	0.1%	0%
Platinum-based drug	264	0.1%	0.1%
Radiographic contrast agent	222	0.8%	0.3%
Angiotensin converting enzyme inhibitor	196	0.2%	0.2%
Tumor necrosis factor blocker	178	0%	0%
Corticosteroid	155	0%	0%
Bradykinin B2 receptor antagonist	131	2.3%	1.4%
Anti-IgE	118	0.1%	0.1%
Microtubule inhibitor	106	0.1%	0.1%
Penicillin-class antibacterial	90	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.5%31

2 to 111.9%117

12 to 171.7%100

18 to 4419.8%1,197

45 to 6428.6%1,732

65 to 7413.6%820

75 and over9.3%563

Age not given24.6%1,490

Patient sex

Female56.6%3,424

Male33.8%2,042

Not given9.7%584

Grey bar: all 20,646,523 reports in the database. 17.6% of these reports give the United States as the country.

Questions about "Laryngeal oedema"

What does "Laryngeal oedema" mean in an adverse event report?

In plain language: swelling of the voice box. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record laryngeal oedema?

6,050 reports through June 2026 (0% of all reports), 330 of them in the latest 12 months.

Which drugs appear most often in these reports?

Oxaliplatin (158), Ibuprofen (123), Ultravist (115), Remicade (105) and Firazyr (98). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.